Important results also came from the NEOS study, a multicenter single-arm open-label phase 2 trial, in which 40 Chinese patients diagnosed with EGFR-mutant NSCLC were enrolled to be treated with neoadjuvant osimertinib therapy for six weeks [51]. Here, EGFR is linked to non-small cell lung carcinoma.